Department of Cardiothoracic Surgery, Castle Hill Hospital, Cottingham, United Kingdom.
Cardiothoracic Surgery Unit, Department of Surgery, University of Benin Teaching Hospital, Benin City, Nigeria.
Pan Afr Med J. 2021 Feb 15;38:169. doi: 10.11604/pamj.2021.38.169.22405. eCollection 2021.
malignant pleural effusion occurs as a consequence of a primary or metastatic malignant process involving the pleura. The aim of pleurodesis is to prevent re-accumulation of the effusion and avoid the need for repeated hospitalization. Povidone iodine has been used in other climes for pleurodesis with good results. The aim of this study is to assess the efficacy and safety of povidone iodine in producing pleurodesis as compared to tetracycline.
the study is a prospective experimental study. The patients are randomized into two groups A (tetracycline-control) and B (povidone iodine). All patients are assessed with chest X-ray after 1 week and 1 month. The responses were ascribed as complete, partial or failure.
thirty patients were recruited into this study, 15 patients in each group A (tetracycline) and B (povidone iodine). The mean age was 45.7±14.24 years. The commonest primary malignancy was Breast cancer (70%) followed by bronchogenic cancer (10%). Seventy three (73%) of the patients in this study had complete response and in 7% pleurodesis failed whilst 20% has partial response. In the povidone group the success rate was 93.4% and in the tetracycline group was 93.3% with a p-value of 0.716. There was no statistical difference in the responses based on the agents used.
malignant pleural effusion is a devastating condition as it heralds the end-of-life processes of a primary malignancy. Povidone iodine is a safe, cheap, effective, widely available and effective pleurodesing agent for use in patients with malignant pleural effusion.
恶性胸腔积液是原发性或转移性恶性肿瘤累及胸膜的后果。胸膜固定术的目的是防止胸腔积液再次积聚,避免反复住院。聚维酮碘在其他地区已被用于胸膜固定术,并取得了良好的效果。本研究旨在评估聚维酮碘在胸膜固定术中的疗效和安全性,并与四环素进行比较。
该研究为前瞻性实验研究。患者随机分为两组 A(四环素对照)和 B(聚维酮碘)。所有患者在 1 周和 1 个月后均行胸部 X 线检查。将反应分为完全、部分或失败。
本研究共纳入 30 例患者,每组 15 例。平均年龄为 45.7±14.24 岁。最常见的原发性恶性肿瘤是乳腺癌(70%),其次是支气管癌(10%)。73%(73%)的患者有完全反应,7%的患者胸膜固定术失败,20%的患者有部分反应。聚维酮组的成功率为 93.4%,四环素组为 93.3%,p 值为 0.716。基于所用药物,反应无统计学差异。
恶性胸腔积液是一种毁灭性的疾病,因为它预示着原发性恶性肿瘤的生命终结过程。聚维酮碘是一种安全、廉价、有效、广泛可用且有效的胸膜固定剂,可用于恶性胸腔积液患者。